Skip to content
TheChatArchiveThe Chat Archive
o3-2025-04-16· OpenAIHugging Face LMArena Human Preference 140K

For ESCC, how many cycles of CCRT is recommended?

From a Chatbot Arena battleThe same person sent this prompt to two anonymous models at once. Compare it with Claudeclaude-sonnet-4-20250514-thinking-32k’s answer.
  1. User

    For ESCC, how many cycles of CCRT is recommended?

  2. Assistant

    How many “cycles” you give with concurrent chemoradiotherapy (CCRT) for esophageal squamous-cell carcinoma (ESCC) depends on the clinical scenario (neoadjuvant vs. definitive), the drug pair you choose, and the guideline you follow.
    Below is a quick-reference summary of the most commonly used evidence-based schedules:

    Clinical intentCommonly used protocol# chemo cycles actually given during RTExtra “consolidation” cycles after RT?Guideline / trial anchor
    Neoadjuvant (pre-operative)CROSS: weekly carboplatin (AUC 2) + paclitaxel 50 mg/m² with 41.4 Gy / 23 fx5 weekly cyclesNovan Hagen NEJM 2012; NCCN Category 1
    Cisplatin 80–100 mg/m² d1 + 5-FU 800–1000 mg/m²/d c.i. d1–4, q3 wk, with 40–45 Gy2 cyclesNoJCOG 9907, RTOG 8911, NCCN
    Definitive (nonsurgical)“Classic” RTOG 85-01: cisplatin 75–100 mg/m² d1 + 5-FU 1000 mg/m²/d c.i. d1–4, q4 wk with 50 Gy2 cycles during RT2 additional cycles (total 4)RTOG 85-01; NCCN (optional)
    Weekly carboplatin (AUC 2) + paclitaxel 50 mg/m² with 50–50.4 Gy5–6 weekly cyclesNoRTOG 0436; NCCN
    FOLFOX (oxaliplatin 85 mg/m² d1, leucovorin, 5-FU bolus + c.i.) q2 wk with 50 Gy3 cycles during RTNoPRODIGE-5/ACCORD 17; NCCN

    Practical take-home numbers • Neoadjuvant CROSS = 5 weekly cycles.
    • Neoadjuvant cisplatin/5-FU = 2 cycles.
    • Definitive “classic” CF = 2 cycles during RT ± 2 consolidation (total 4).
    • Definitive weekly Carbo/Taxol = 5–6 cycles (one per week of radiation).

    Why the variation?

    1. Toxicity: adding consolidation cycles after 50 Gy increases hematologic and GI toxicity without clear survival benefit, so many centers now omit them.
    2. Logistics: weekly regimens (Carbo/Taxol) fit seamlessly with daily RT and are better tolerated, especially in frail patients.
    3. Evidence base: CROSS demonstrated a pathologic complete-response rate of ≈30% and survival benefit, so its 5 weekly cycles have become the standard for trimodality therapy.

    Bottom line There is no single “magic” cycle number for every ESCC case. The most widely adopted regimens use either: • 5 weekly cycles (Carbo/Taxol) with radiation, or
    • 2 cycles of cisplatin/5-FU during radiation (±2 more afterwards).

    Always individualize based on performance status, organ function, and institutional protocol.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.